Abbott Laboratories $ABT Shares Acquired by Rockland Trust Co.

Rockland Trust Co. increased its position in shares of Abbott Laboratories (NYSE:ABT) by 26.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 110,519 shares of the healthcare product maker’s stock after purchasing an additional 23,359 shares during the period. Rockland Trust Co.’s holdings in Abbott Laboratories were worth $14,803,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. IMG Wealth Management Inc. grew its position in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after buying an additional 167 shares in the last quarter. Cloud Capital Management LLC acquired a new position in Abbott Laboratories during the 3rd quarter worth $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth about $31,000. Anfield Capital Management LLC lifted its position in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC acquired a new position in Abbott Laboratories in the second quarter worth about $32,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT opened at $111.11 on Tuesday. The company has a market capitalization of $193.21 billion, a PE ratio of 29.87, a PEG ratio of 1.76 and a beta of 0.75. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The company’s 50 day moving average price is $120.52 and its 200 day moving average price is $126.80. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter last year, the business posted $1.34 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Analysts Set New Price Targets

Several research firms have commented on ABT. Argus decreased their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Evercore dropped their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group decreased their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Finally, Leerink Partners cut their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.